Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 649 | $401,491,365 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
17 Aug 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 16 Aug 2022 | Sale | 325 | 646.44 | 210,093 | D |
17 Aug 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 16 Aug 2022 | Sale | 329 | 642.53 | 211,392 | D |
26 Dec 2023 16:08 | REGN | REGENERON PHARMACEUTICALS Inc | FENIMORE CHRISTOPHER R. | SVP Controller | 22 Dec 2023 | Sale | 250 | 846.27 | 211,568 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 226 | 938.13 | 212,017 | D |
17 Aug 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 16 Aug 2022 | Sale | 332 | 644.49 | 213,971 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 297 | 721.74 | 214,357 | D |
03 Oct 2022 16:05 | REGN | REGENERON PHARMACEUTICALS Inc | TESSIER-LAVIGNE MARC | Director | 29 Sep 2022 | Sale | 321 | 687.9 | 220,816 | D |
03 May 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 01 May 2024 | Sale | 250 | 889.41 | 222,352 | D |
30 Dec 2022 16:10 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 28 Dec 2022 | Sale | 311 | 716.08 | 222,701 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 228 | 987.46 | 225,141 | D |
10 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | BROWN MICHAEL S | Director | 08 Nov 2022 | Sale | 300 | 753.66 | 226,098 | D |
12 Dec 2023 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 11 Dec 2023 | Sale | 270 | 838.44 | 226,379 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 240 | 947.81 | 227,474 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 315 | 730.57 | 230,130 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 235 | 982.66 | 230,925 | D |
04 Jan 2024 16:17 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 02 Jan 2024 | Sale | 274 | 873.91 | 239,451 | D |
03 Apr 2024 16:05 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 01 Apr 2024 | Sale | 250 | 964.73 | 241,182 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 336 | 719.62 | 241,792 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 333 | 727.17 | 242,148 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 250 | 983.91 | 245,978 | D |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 24 Aug 2023 | Sale | 300 | 837.53 | 251,259 | D |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | POON CHRISTINE A | Director | 23 Aug 2023 | Sale | 300 | 837.92 | 251,376 | D |
02 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 01 Feb 2024 | Sale | 273 | 945.61 | 258,152 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 275 | 941.41 | 258,888 | D |
08 Aug 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 05 Aug 2022 | Sale | 424 | 617.43 | 261,790 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 361 | 728.44 | 262,967 | D |
18 Oct 2022 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | LANDRY ROBERT E | EVP Finance CFO | 17 Oct 2022 | Sale | 358 | 739.5 | 264,741 | D |
15 Nov 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Nov 2023 | Sale | 330 | 803.38 | 265,115 | D |
25 Nov 2022 13:07 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 23 Nov 2022 | Sale | 373 | 737.37 | 275,039 | D |
15 Nov 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Nov 2023 | Sale | 347 | 795.38 | 275,997 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 281 | 985.72 | 276,987 | D |
15 Nov 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Nov 2023 | Sale | 347 | 802.63 | 278,513 | D |
06 Dec 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 05 Dec 2023 | Sale | 345 | 820.54 | 283,086 | D |
08 Sep 2022 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 06 Sep 2022 | Sale | 500 | 577.07 | 288,535 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 295 | 980.64 | 289,289 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 299 | 988.76 | 295,639 | D |
17 May 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 15 May 2024 | Sale | 303 | 982.29 | 297,634 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 305 | 984 | 300,120 | D |
08 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 07 Nov 2022 | Sale | 404 | 747.2 | 301,869 | D |
06 Dec 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 05 Dec 2023 | Sale | 372 | 812.57 | 302,276 | D |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 24 Aug 2023 | Sale | 363 | 841.15 | 305,337 | D |
15 Nov 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Nov 2023 | Sale | 382 | 800.55 | 305,810 | D |
08 Aug 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 05 Aug 2022 | Sale | 502 | 619.64 | 311,059 | D |
13 Sep 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 12 Sep 2022 | Sale | 435 | 718.5 | 312,548 | D |
08 Sep 2022 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 06 Sep 2022 | Sale | 550 | 579.85 | 318,918 | D |
08 Aug 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 05 Aug 2022 | Sale | 521 | 618.27 | 322,119 | D |
27 Mar 2023 16:41 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | President and Chief Scientific | 23 Mar 2023 | Sale | 400 | 810.3 | 324,120 | I |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | FENIMORE CHRISTOPHER R. | SVP Finance & CFO | 09 Feb 2024 | Sale | 344 | 950.49 | 326,969 | D |
08 Aug 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 05 Aug 2022 | Sale | 535 | 616.4 | 329,774 | D |
17 Aug 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 16 Aug 2022 | Sale | 537 | 641.47 | 344,469 | D |
05 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 01 Mar 2024 | Sale | 358 | 967.5 | 346,365 | D |
08 Sep 2022 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 06 Sep 2022 | Sale | 602 | 584.57 | 351,911 | D |
05 Oct 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 03 Oct 2022 | Sale | 500 | 705.39 | 352,695 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 375 | 950.45 | 356,419 | D |
17 May 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 15 May 2024 | Sale | 373 | 988.36 | 368,658 | D |
17 May 2024 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 16 May 2024 | Sale | 379 | 978.18 | 370,730 | D |
08 Aug 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 05 Aug 2022 | Sale | 610 | 608.7 | 371,307 | D |
10 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | BROWN MICHAEL S | Director | 08 Nov 2022 | Sale | 500 | 748.49 | 374,245 | I |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 521 | 729.37 | 380,002 | D |
03 Oct 2022 16:05 | REGN | REGENERON PHARMACEUTICALS Inc | TESSIER-LAVIGNE MARC | Director | 29 Sep 2022 | Sale | 554 | 691.59 | 383,141 | D |
26 Dec 2023 16:08 | REGN | REGENERON PHARMACEUTICALS Inc | FENIMORE CHRISTOPHER R. | SVP Controller | 21 Dec 2023 | Sale | 456 | 843.79 | 384,768 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 532 | 731.49 | 389,153 | D |
17 May 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 15 May 2024 | Sale | 406 | 971.28 | 394,340 | D |
08 Feb 2023 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | BROWN MICHAEL S | Director | 06 Feb 2023 | Sale | 500 | 797 | 398,500 | I |
08 Sep 2022 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 06 Sep 2022 | Sale | 688 | 580.44 | 399,343 | D |
13 Sep 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 12 Sep 2022 | Sale | 572 | 713.67 | 408,219 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 439 | 937.94 | 411,756 | D |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | POON CHRISTINE A | Director | 23 Aug 2023 | Sale | 500 | 841.05 | 420,525 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 444 | 952.4 | 422,866 | D |
05 Oct 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 03 Oct 2022 | Sale | 600 | 705.39 | 423,234 | D |
17 May 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 15 May 2024 | Sale | 442 | 986.4 | 435,989 | D |
03 Oct 2022 16:05 | REGN | REGENERON PHARMACEUTICALS Inc | TESSIER-LAVIGNE MARC | Director | 29 Sep 2022 | Sale | 637 | 688.71 | 438,708 | D |
08 Aug 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 05 Aug 2022 | Sale | 724 | 607.47 | 439,808 | D |
02 Dec 2022 16:05 | REGN | REGENERON PHARMACEUTICALS Inc | LANDRY ROBERT E | EVP Finance CFO | 02 Dec 2022 | Sale | 582 | 756.5 | 440,283 | D |
12 Sep 2022 16:31 | REGN | REGENERON PHARMACEUTICALS Inc | BASSLER BONNIE L | Director | 09 Sep 2022 | Sale | 609 | 741 | 451,269 | D |
17 Aug 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 16 Aug 2022 | Sale | 701 | 647.73 | 454,059 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 477 | 958.34 | 457,128 | D |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | FENIMORE CHRISTOPHER R. | SVP Finance & CFO | 09 Feb 2024 | Sale | 487 | 951.39 | 463,327 | D |
13 Sep 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 12 Sep 2022 | Sale | 647 | 717.59 | 464,281 | D |
25 Nov 2022 13:07 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 23 Nov 2022 | Sale | 629 | 747.28 | 470,039 | D |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 08 Feb 2024 | Sale | 500 | 945 | 472,500 | D |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 09 Feb 2024 | Sale | 500 | 955 | 477,500 | D |
03 Oct 2022 16:05 | REGN | REGENERON PHARMACEUTICALS Inc | TESSIER-LAVIGNE MARC | Director | 29 Sep 2022 | Sale | 692 | 690.65 | 477,930 | D |
08 Sep 2022 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 06 Sep 2022 | Sale | 822 | 581.44 | 477,944 | D |
30 Dec 2022 16:10 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 28 Dec 2022 | Sale | 679 | 710.63 | 482,518 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 512 | 959.36 | 491,192 | D |
26 Feb 2024 16:07 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 23 Feb 2024 | Sale | 500 | 985 | 492,500 | D |
17 May 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 15 May 2024 | Sale | 504 | 979.87 | 493,854 | D |
28 Feb 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 26 Feb 2024 | Sale | 500 | 990 | 495,000 | D |
17 Aug 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 16 Aug 2022 | Sale | 766 | 648.78 | 496,965 | D |
28 Feb 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | SING GEORGE L | Director | 26 Feb 2024 | Sale | 500 | 995 | 497,500 | D |
25 Nov 2022 13:07 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 23 Nov 2022 | Sale | 686 | 735.57 | 504,601 | D |
27 Mar 2023 16:41 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | President and Chief Scientific | 23 Mar 2023 | Sale | 642 | 803.3 | 515,719 | I |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 24 Aug 2023 | Sale | 617 | 842.66 | 519,921 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 545 | 955.54 | 520,769 | D |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 24 Aug 2023 | Sale | 625 | 836.32 | 522,700 | D |
14 Dec 2023 16:07 | REGN | REGENERON PHARMACEUTICALS Inc | BASSLER BONNIE L | Director | 13 Dec 2023 | Sale | 610 | 870 | 530,700 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 576 | 953.77 | 549,372 | D |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 24 Aug 2023 | Sale | 667 | 838.37 | 559,193 | D |
27 Mar 2023 16:41 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | President and Chief Scientific | 23 Mar 2023 | Sale | 700 | 806.47 | 564,529 | I |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)